

HER2 Positive Treatment with Trastuzumab


In this lesson you will learn the required documentation for the **MIPS #450 Appropriate Treatment for Patients with Stage I (T1c) – III HER2 Positive Breast Cancer** quality measure.

Required fields are:


- Stage I (T1c) - III Breast Cancer
- HER2 Positive
- Chemotherapy regimen and Trastuzumab (or biosimilar)
 - Both chemotherapy and HER2-targeted therapy to occur within six months of pathologic staging to meet the numerator

Exceptions:

- Exceptions for medical or patient reasons can be documented in the **Clinical Quality Exception** care plan



1. To enter the **breast cancer diagnosis** and **HER2** status, click **ADD PROBLEM**.



2. Type in patient diagnosis and select **Problem** from drop-down list.
3. Enter **date of diagnosis**.
4. Click **NEXT**.

iKnowMedSM Generation 2

New Problem

Problem (required)
Infiltrating ductal breast cancer

Date of Diagnosis
Status
Active
Comment

Details
Stage Date 04/24/2025, HER2 status: Positive
View More

ICD-10 (required)
HCC C50.221 - Malignant neoplasm of upper-inner quadrant of right male breast

Additional Codes
ER Status (needs coding)

Tumor Type
Node
Metastasis
Grade-Nottingham
ER Status
PR Status
HER2 status
Oncotype < 11
Stage
Prognostic Details
Extent of Disease
Disease State
Lymph Node Involvement

HER2 status clear
☒ Positive: IHC 3+ or IHC 2+/ISH-positive
☐ Low: IHC 1+ or IHC 2+/ISH-negative
☐ Negative: IHC 0
☐ Unknown
 Other

SAVE & ADD ANOTHER SAVE & CLOSE CANCEL NEXT

5. Enter the **HER2 Status**.

6. Click **NEXT** or scroll down to complete staging.

Staging Add a Stage

Stage Date
04/24/2025

Staging Type
Location


Tumor Type
Node
Metastasis
Grade-Nottingham
ER Status
PR Status
HER2 status
Positive
Oncotype < 11
Stage

Tumor Type clear
☐ T0: No evidence of primary tumor
☐ Tis (DCIS): Ductal carcinoma in situ
 Tis (Paget's): Paget disease of the nipple NOT associated with invasive carcinoma and/or carcinoma in situ (DCIS) in the underlying breast parenchyma.
☐ Carcinomas in the breast parenchyma associated with Paget disease are categorized based on the size and characteristics of the parenchymal disease, although the presence of Paget disease should still be noted.
☐ T1mi: Tumor <=1 mm in greatest dimension
☐ T1a: Tumor >1 mm but <=5 mm in greatest dimension
☐ T1b: Tumor >5 mm but <=10 mm in greatest dimension
☐ T1c: Tumor >10 mm but <=20 mm in greatest dimension
☐ T2: Tumor >20 mm but <=50 mm in greatest dimension

SAVE & ADD ANOTHER SAVE & CLOSE CANCEL NEXT

7. Select appropriate Tumor Type, not required for the measure, but best practice to fully document TNM.

iKnowMedSM Generation 2



Staging Add a Stage

Stage Date 04/24/2025

Staging Type

Location

Tumor Type

Node

Metastasis

Grade-Nottingham

ER Status

PR Status

HER2 status Positive

Oncotype < 11

Stage

Node clear

☐ pN0: No regional lymph node metastasis identified or ITCs only

☐ pN0(i+): ITCs only (malignant cell clusters no larger than 0.2 mm) in regional lymph node(s)

☐ pN0(mol+): Positive molecular findings by reverse transcriptase polymerase chain reaction (RT-PCR); no ITCs detected

☐ pN1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2 mm)

☐ pN1a: Metastases in 1-3 axillary lymph nodes, at least one metastasis larger than 2 mm

☐ pN1b: Metastases in ipsilateral internal mammary sentinel nodes, excluding ITCs


☐ pN1c: pN1a and pN1b combined

☐ pN2a: Metastases in 4-9 axillary lymph nodes (at least one tumor deposit larger than 2 mm)

☐ pN2b: Metastases in clinically detected

SAVE & ADD ANOTHER SAVE & CLOSE CANCEL NEXT

8. Select appropriate Node, not required for the measure, but best practice to fully document TNM.



Staging Add a Stage

Stage Date 04/24/2025

Staging Type

Location

Tumor Type

Node

Metastasis

Grade-Nottingham

ER Status

PR Status

HER2 status Positive

Oncotype < 11

Stage

Metastasis clear

☐ M0: No clinical or radiologic evidence of distant metastases

☐ cM0(i+): No clinical or radiographic evidence of distant metastases in the presence of tumor cells or deposits no larger than 0.2 mm detected microscopically or by molecular techniques in circulating blood, bone marrow or other nonregional nodal tissue in a patient without symptoms or signs of metastases

☐ cM1: Distant metastases detected by clinical and radiographic means

☐ pM1: Any histologically proven metastases in distant organs; or if in non-regional nodes, metastases greater than 0.2 mm

Other

10

SAVE & ADD ANOTHER SAVE & CLOSE CANCEL NEXT

9. Select metastasis, if applicable, not required for the measure, but best practice to fully document TNM.

NOTE on Staging and TNM Information: While not always required for every MIPS measure, it is always best clinical practice to document all staging and TNM information as fully as possible. ***Practices in the Enhancing Oncology Model (EOM) will find this complete, consistent documentation extremely helpful in Clinical Data Element Reporting.***

10. Click **SAVE & CLOSE**.

iKnowMedSM Generation 2

Sharon's Dashboard Cheryl Chemo (30 / F) x

> Cheryl Chemo (30 / F) | ! | < > | < > | < > | DOB: 10/23/1990 MRN: LD102301 Attending: Learn

Chart Summary Clinical Profile **Flowsheet** Orders Results D

Flowsheet Find: Find a result or order

5/20/21 (Thu) 5/27/21 (Thu)

	C1D1	C1D8
▼ Anastrozole + Trastuzumab IV BIOSIMILAR ▼		
▼ BIOSIMILAR ▼		
◀ Kanjinti (Trastuzumab Biosimilar IV) ⋮	230 mg (4 mg/kg)	120 mg (2 mg/kg)
▼ HORMONE THERAPY ▼		
◀ Anastrozole Oral ⋮	Rx 1 mg qday	
▼ **PRN** HYPERSENSITIVITY MEDS ▼		
◀ Epinephrine IM ⋮	0.3 mg PRN	0.3 mg PRN
◀ Diphenhydramine IV ⋮	50 mg PRN	50 mg PRN

11. Using the **Orders Tab**, enter regimen. Select order and complete all required fields. Patients who meet this measure will receive both **chemotherapy and Trastuzumab**. This will be visible in the Flowsheet tab.

> Cheryl Chemo (30 / F) | ! | < > | < > | < > | DOB: 10/23/1990 MRN: LD102301 Attending: Learn

Profile Flowsheet Orders Results Documents **Demographics**

Demographics

▶ Patient Preferences

▶ Preferred Pharmacy

▶ Drug Benefit Plan

▶ Intake Documents

▶ Insurance

▼ Patient Transfers 13

ADD INBOUND PATIENT TRANSITION 14 OUTBOUND PATIENT TRANSITION EDIT REMOVE

12. When the patient's treatment started before the patient transitioned to the provider, an Inbound transition of care should be documented to exclude the patient. Click **Demographics**.

13. Click **Patient Transfers**. Click the ▶ to unzip Patient Transfers.


14. Click **ADD INBOUND PATIENT TRANSITION**.

iKnowMedSM Generation 2




In the **Add Inbound Patient Transition** window, complete all fields with a red asterisk:

- **Transition Date**
- **Receiving Physician**
- **Patient History Received**



15. Document the **Transition Date**.
16. Complete the **Patient History Received** area.
17. Use the drop-down list to select the provider for **Referred From**.
18. Click **SAVE**.



19. To document an exception for a medical or patient reason, click **CARE PLAN**.
20. Click **ADD CAREPLAN**.

iKnowMedSM Generation 2

Add Survey * required

Date of Service: 05/20/2021 12:30 PM

Type *: Select

User:

SAVE

21. Select **Clinical Quality Exceptions** from the drop-down list.
22. Click **SAVE**.

Clinical Quality Exceptions (Date of service: 05/20/2021)

▼ Date of Service

05/20/2021 TODAY

▼ Prostate Cancer / Adjuvant Hormonal Therapy

Decision Date

TODAY

► Medical Reasons

► Patient Reasons

▼ Breast Cancer / Trastuzumab

Decision Date

05/20/2021 TODAY

► Medical Reasons

► Patient Reasons

23. Use the calendar widget to enter the **Date of Service** or click TODAY.
24. Click the ► to open **Breast Cancer / Trastuzumab** exceptions.
25. Use the calendar widget to enter **Decision Date** or click TODAY.

iKnowMedSM Generation 2

▼ Breast Cancer / Trastuzumab

Decision Date
05/20/2021

▼ Medical Reasons **26**

- ☐ Treatment not indicated (situation)
- ☐ Medical contraindication (finding)
- ☐ Treatment not tolerated (situation)
- ☐ Drug allergy (disorder)
- ☐ Drug interaction (finding)
- ☐ Patient transfer to practice after initiation of chemotherapy
- ☐ Other

▶ Patient Reasons **27**

26. Click  to unzip the **Medical Reasons** to enter a medical exception.
27. Click the appropriate check box for the **medical exception** reason.

▼ Breast Cancer / Trastuzumab

Decision Date
05/20/2021

▶ Medical Reasons

▼ Patient Reasons **28**



- ☐ Refusal of treatment by patient (situation)
- ☐ Financial problem (finding)
- ☐ Patient has moved away (finding)

29

▼ Breast Cancer / Hormonal Therapy

Decision Date

30

28. Click  to unzip the **Patient Reasons** to enter a patient exception.
29. Click the appropriate check box to document the **Patient Reason** for exception.
30. Click .

This concludes the lesson for the **MIPS #450 Appropriate Treatment for Patients with Stage I (T1c) – III HER2 Positive Breast Cancer** quality measure.